Intralesional Alpha Interferon Therapy in Papillary Superficial Transitional Cell Carcinoma of the Bladder A Pilot Study

Abstract

The tolerability, toxicity and therapeutic efficacy of recombinant interferon alpha-2a (rIFN alpha-2a), administered by intralesional injection, were evaluated in 15 patients with papillary superficial transitional cell carcinoma of the bladder, rIFN alpha-2a was delivered endoscopically in a single weekly dose of 3 x 10(6) IU for 4 weeks (total 12 x 10(6) IU). Transurethral resection of residual tumours was then performed. The response to treatment was assessed according to ultrasonographic, endoscopic and pathological findings. One patient achieved complete remission, 6 partial remission, 6 minor remission and 2 stabilisation of disease. All patients completed the course of treatment. A mild, transient, flu-like syndrome was documented after every injection. Immunological findings suggest that the antitumour effects of rIFN alpha 2a are not mediated through the immune system.

Role of Interferon-Alpha-2b in the Prevention of Superficial Carcinoma of the Bladder Recurrence

“…We focussed our study on the therapeutic efficacy and adverse effects of low-dose (total of 72 million IU over 8 weeks) intravesical IFN in the prevention of recurrence of TCC. We achieved a good overall response rate of 65% and a disease-free interval of 21.4 months, which compare more favorably with the 47% response rate and 19.3-month disease-free interval reported in an earlier study by Distasi et al [3]. Kostakapoulos ct al.…”

Ερευνητική Μελέτη Της Τοπικής Απάντησης Σε Επιφανειακό Καρκίνο Της Ουροδόχου Κύστης Μετά Από Χορήγηση Ανοσοτροποποιητικών Παραγόντων

“…Η επικρατέστερη οδός χορήγησης της ιντερφερόνης-α είναι η ενδοκυστική έγχυση. Η ενδο-ογκική έγχυση της ουσίας και η ενδοµυϊκή χορήγηση έχουν πλέον πρακτικά εγκαταλειφθεί [256][257][258] . Ιστορικά, η πρώτη ενδοκυστική χορήγηση ιντερφερόνης-α (λεµφοβλαστοειδούς προέλευσης) σε επιφανειακό καρκίνο της ουροδόχου κύστης πραγµατοποιήθηκε το 1986 από τον Oliver και συν 259 .…”